Epinephrine is the only effective treatment for anaphylaxis
Anaphylaxis is a severe allergic reaction that can potentially lead to death if not promptly treated. Allergic reactions typically begin suddenly after exposure to an allergen, which may be a food, medication, insect sting, or another trigger. Anaphylaxis can occur in anyone at any time; it can sometimes be triggered by allergens that a person has only had mild reactions to in the past — or to which they have never reacted to before. Recognizing anaphylaxis A mild allergic reaction may consist of hives, itching, flushing, swelling of the lips or tongue, or some combination of these. However, throat swelling or tightening, trouble breathing, wheezing, shortness of breath, cough, lightheadedness, fainting, abdominal cramps, nausea, vomiting, diarrhea, or a sense of impending doom, are all symptoms of anaphylaxis. The symptoms of an anaphylactic reaction can vary from one episode to the next, even in the same individual. How should anaphylaxis be treated? It is important to quickly recognize anaphylaxis so it can be promptly treated with epinephrine, the first-line treatment for anaphylaxis. Epinephrine is a hormone made by the adrenal glands. It works within minutes to prevent progression and reverse the symptoms of anaphylaxis. People may wonder if they should administer epinephrine if they suspect — but aren’t sure — that they are having an anaphylactic reaction. The answer is yes. Epinephrine should be administered without delay if there is any concer...
CONCLUSIONS: Xyloglucan/gelose plus ORS was effective and safe in treating acute diarrhea in children. PMID: 33028102 [PubMed - as supplied by publisher]
Boosting the sensitivity of in vitroβ-lactam allergy diagnostic tests. Chem Commun (Camb). 2020 Oct 14;56(80):11973-11976 Authors: Peña-Mendizabal E, Morais S, Maquieira Á Abstract The synthesis of structurally new haptens and the development of suitable antigens are essential for boosting the sensitivity of drug allergy diagnostic testing. Unprecedented structural antigens for benzylpenicillin and amoxicillin are characterised and evaluated in a cohort of 70 subjects with a turnkey solution based on consumer electronics. PMID: 33033809 [PubMed - in process]
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Xiaoqin Liu, Trine Munk-Olsen, Clara Albiñana, Bjarni J. Vilhjálmsson, Emil M. Pedersen, Vivi Schlünssen, Marie Bækvad-Hansen, Jonas Bybjerg-Grauholm, Merete Nordentoft, Anders D. Børglum, Thomas Werge, David M. Hougaard, Preben B. Mortensen, Esben Agerbo
Publication date: Available online 9 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Manuel Jorge Rial, Marcela Valverde, Victoria del Pozo, Francisco Javier González-Barcala, Carlos Martínez-Rivera, Xavier Muñoz, José María Olaguibel, Vicente Plaza, Elena Curto, Santiago Quirce, Pilar Barranco, Javier Domínguez-Ortega, Joaquin Mullol, César Picado, Antonio Valero, Irina Bobolea, Ebymar Arismendi, Paula Ribó, Joaquín Sastre
Purpose of Study: Explore the perceptions of primary care physicians (PCPs) from community health care centers (CHCs) in Franklin County, Ohio, regarding factors that contribute to their inability to consistently provide sustainable asthma management services to their uninsured patient population. Primary Practice Setting: Asthmatic patients are not consistently receiving sustainable asthma management in CHCs in Ohio. Primary care physicians in CHCs play a pivotal role in closing health care gaps for asthmatic patients. To minimize the barriers that impede the efforts of PCPs to control asthma for their uninsured pati...
CONCLUSION: Our study provides additional evidence to help design allergy interventions. PMID: 33031690 [PubMed - as supplied by publisher]
Publication date: Available online 9 October 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Osamu Matsuno, Seijiro Minamoto
Publication date: Available online 8 October 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Noriyuki Ohkura, Masaki Fujimura, Johsuke Hara, Yusuke Nakade, Miki Abo, Takashi Sone, Hideharu Kimura, Kazuo Kasahara
Publication date: Available online 8 October 2020Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Francesco Menzella, Patrizia Ruggiero, Carla Galeone, Chiara Scelfo, Diego Bagnasco, Nicola Facciolongo
Publication date: Available online 8 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): M.R. Goldberg, M.Y. Appel, R. Nega, M.B. Levy, Naama Epstein-Rigby, L. Nachshon, A. Elizur